NZNataliya V. Zaytseva

Nataliya V. Zaytseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nataliya V. Zaytseva has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic kidney disease in patients with diabetes mellitus: new challenges

    by M. S. Shamkhalova, O. Y. Sukhareva, S. A. Martynov, A. S. Severina, O. K. Vikulova, N. P. Trubitsyna, O. N. Naumenko, N. V. Zaytseva, M. V. Shestakova, I. I. Dedov, et al.

    Chronic kidney disease (CKD) is a supranosological concept, defined as a disorder of the structure and/or function of the kidneys for 3 months or more that leads to health consequences. CKD develops in 20–40% of patients with diabetes mellitus (DM). Dynamic analysis of epidemiological indicators of CKD in patients with diabetes mellitus points to the prevalence increase of this pathology in the Russian Federation in 2010–2022. Improved quality of diagnostics of earlier stages complications, a decrease in the risk of cardiovascular events (the leading cause of death) and end-stage renal failure at a later age and with a longer duration of diabetes are noted as well. The development of tools for predicting the risk of the pathology progression and its complications has made it possible to improve patient monitoring and routing. Current international and domestic recommendations emphasize a comprehensive approach to the treatment of CKD, including lifestyle modification, evidence-based pharmacological treatments aimed at preserving organ function, and improving cardiovascular prognosis. An optimal model of care for patients with diabetes and CKD, aimed at multidisciplinary care and adapted according to the severity of CKD, will lead to the best outcomes for the individual patient and society.


  • Open Access

    Chronic kidney disease in patients with long-term type 1 diabetes mellitus

    by M. I. Yevloyeva, M. S. Arutyunova, A. S. Severina, N. P. Trubitsyna, N. V. Zaitseva, M. S. Shamhalova, M. V. Shestakova

    BACKGROUND: Patients with type 1 diabetes mellitus (T1D) have an earlier age of onset and a longer course of the disease, already by middle age they have the development of microand macrovascular diabetic complications that reduce the quality and duration of life.AIM: To evaluate the prevalence of chronic kidney disease (CKD) and other late complications of T1D depending on renal dysfunction in the population of patients with T1D with disease duration of 20 and more years, who underwent examination and treatment in Endocrinology Research Centre.MATERIALS AND METHODS: A one-stage single-center epidemiological non-randomised study was conducted using the database of Endocrinology Research Centre with the study of 500 patients’medical histories with long-term T1D (20 years and mores), without kidney damage and with CKD at different stages (CKD C1–C5, C5D, after transplantation), examined and treated from 2011 to 2023.RESULTS: Normal renal function was observed in 10.8% of patients (n=54). Terminal stage of CKD was reached in 28.0% (n=140), of which 12.4% were on renal replacement therapy with program hemodialysis (RRT-HD), and 12.0% after isolated kidney transplantation or combined kidney and pancreas transplantation, the rest were at different stages of CKD. Normoalbuminuria was observed in 15.4% (n=77) among 500 patients. The prevalence of late complications of DM among the examined patients was high and increasing with the progression of renal dysfunction: diabetic retinopathy was diagnosed in 96% of patients, distal symmetrical polyneuropathy — in 97% of patients, various forms of autonomic neuropathy — in more than half of patients. About 60% of patients had diagnosed arterial atherosclerosis in the legs, about one third — atherosclerosis of brachiocephalic arteries, 23% — confirmed coronary heart disease, and suffered cardiovascular events (myocardial infarction, acute cerebral circulation disorder) — 19% of patients, about half of whom had CKD of different severity. Factors for increased risk of cardiovascular disease: estimated glomerular filtration rate (eGFR)2, OR=7.1; 95% CI 3.6–8.4; p2 OR=8.7; 95% CI 2.8–8.4; p2 OR=14; 95% CI 6.3–31.3; p 30 mg/g OR=2.4; 95% CI 1.6–3.6; pCONCLUSION: Despite a significant reduction in the risk of developing CKD in individuals with T1D debut between 1996 and 2002, renal dysfunction is a frequent complication in patients with a long disease course, combining with other late complications and contributing to a high risk of terminal stage of CKD and cardiovascular events. Early age of T1D debut increases the risk of terminal CKD.


  • Open Access

    Effect of components of the renin-angiotensin system, rs2106809 polymorphism of the ACE2 gene, and therapy with RAS blockers on the severity of COVID-19

    by Z. T. Zuraeva, O. K. Vikulova, N. M. Malysheva, L. V. Nikankina, N. V. Zaytceva, O. Y. Sukhareva, M. S. Shamhalova, M. V. Shestakova, N. G. Mokrysheva, О. Ю. Сухарева

    BACKGROUND: Angiotensin-converting enzyme 2 (ACE2) is a key component of the renin-angiotensin system (RAS), providing counter-regulation of its effects and, simultaneously, a receptor for the SARS-CoV-2 entering. It is suggested that factors regulating the balance of the major components of RAS, including ACE2 gene polymorphism, therapy with RAS blockers (ACE inhibitors and angiotensin receptor blockers) — may affect the severity of COVID-19.AIM: The aim of the study was to investigate the effect of RAS components, the relationship of ACE2 gene polymorphism rs2106809 and ACEi/ARBs therapy with the COVID-19 severity.MATERIALS AND METHODS: The study included patients with COVID-19 hospitalized in Endocrinology research centre (n = 173), who were divided into groups of moderate and severe course. Determination of RAS components was performed by ELISA, identification of polymorphism by PCR. Statistical analysis was performed using nonparametric statistical methods; differences in the distribution of genotype frequencies were assessed using Fisher’s exact test χ2.RESULTS: The groups differed significantly in age, blood glucose levels, and inflammatory markers: leukocytes, neutrophils, IL-6, D-dimer, C-reactive protein, ferritin and liver enzymes, which correlated with the severity of the disease. When comparing patients in terms of ACE, ACE2, angiotensin II, ADAM17 there were no statistically significant differences between the groups (p=0.544, p=0.054, p=0.836, p=1.0, respectively), including the distribution by gender (in men: p=0.695, p=0.726, p=0.824, p=0.512; in women: p=0.873, p=0.196, p=0.150, p=0.937). Analysis of the distribution of AA, AG, and GG genotypes of the rs2106809 polymorphism of the ACE2 gene also revealed no differences between patients: χ2 1.35, p=0.071 in men, χ2 5.28, p=0.244 in women. There were no significant differences in the use of RAS blockers between groups with different course severity: χ2 0.208, p=0.648 for ACEi, χ2 1.15, p=0.283 for ARBs.CONCLUSION: In our study, the influence of activation of RAS components (ACE, ACE2, AT II, ADAM17) and ACE2 gene polymorphism on the severity of COVID-19 course was not confirmed. The severity of COVID-19 course correlated with the level of standard inflammatory markers, indicating the general principles of the infection as a systemic inflammation, regardless of the genetic and functional status of the RAS.


  • Open Access

    Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action

    by N. P. Trubitsyna, N. V. Zaitseva, A. S. Severinа, M. S. Shamkhalova

    Diabetes mellitus type 2 (DM2) is socially important disease, becoming non-infectious epidemic due to increasing prevalence. Chronic kidney disease (CKD) is one of the most common diabetic complications. Kidney injury signs and/or estimated glomerular filtration rate (eGFR) decrease are seen in 40-50% of patients with DM2. Three groups of factors are considered to be the basis of CKD development and progression in DM2: metabolic, hemodynamic, inflammation and fibrosis. Existing drugs that are used in patients with CKD and DM2 first of all target hemodynamic and metabolic disturbances, but their action against inflammation and fibrosis is indirect. Hyperactivation of mineralocorticoid receptors (MR) is considered as one of the main trigger factors of end-organ damage in patients with DM2 due to inflammation and fibrosis. Development of selective nonsteroidal MR antagonists (MRA) as a new class of medications is directed to demonstrate positive effects from blocking this pathophysiological pathway of CKD development and overcome the steroidal MRAs’ shortcomings. Hence pathophysiological hyperactivation of MR with subsequent inflammation and fibrosis in patients with CKD in DM2 is considered a promising therapeutic target for the new drugs with cardionephroprotective effect.


  • Open Access

    Feсal microbiota transplantation in the format of complex therapy in obesive siblings: clinical case

    by E. V. Pokrovskaya, E. S. Zhgun, E. A. Shestakova, I. A. Sklyanik, I. V. Fedushkina, E. I. Olekhnovich, D. N. Konanov, Д. А. Кардонский, Yu. V. Kislun, E. A. Sorokina, et al.

    Obesity and associated metabolic diseases are often accompanied by changes in the gut microbiota leading to metagenome gene diversity decrease. Fecal microbiota transplantation (FMT) is one of the most effective methods for correcting the intestinal microflora. FMT obtained from healthy donors has been proven to be an effective treatment of infections caused by Clostridium difficile. The use of FMT for correction of metabolic disorders is promising, however, data on its application is limited and has contradictory results. In our work, two patients (siblings) presented with obesity grade II and various types of diabetes mellitus (DM): the older brother (44 years old) with diabetes mellitus type 2 (DM 2), a younger brother (39 years old) with diabetes mellitus type 1 (DM 1). Both patients underwent FMT as part of complex antidiabetic therapy. During the course of treatment, a decrease in body weight was noted in both patients (4–5 kg for the first month of observation, then -1–2 kg per month). One year after FMT, a patient with type 2 diabetes showed a decrease in the severity of insulin resistance (IR), measured by the hyperinsulinemic euglycemic clamp test (initial M-index 2.42 mg/kg*min, after 1 year — 3.83 mg/kg* min) as well as the maintenance of satisfactory carbohydrate metabolism compensation against the diminishing the hypoglycemic therapy. In a patient with DM 1, no significant dynamics of carbohydrate exchange indices, including detected glycated hemoglobin (HbA1c), insulin dose and IR were during the observation period. Metagenomic sequencing of stool samples (n = 20) collected from both patients before and within 1 year after FMT showed no significant changes in the taxonomic profile of the microbiota at the level of microbial families. Metabolomic analysis of the composition of feces showed no directed changes in the composition of metabolites after the FMT procedure, the nature of changes within the samples from each patient during the entire study period was random. Thus, FMT had no effect on the course of DM1, but served as a starting point for weight loss and improvement glucose profile in DM2. However, convincing data confirming a causal correlation between FMT and improvement in the course of T2DM have not been obtained.


  • Open Access

    Diabetes mellitus, chronic pancreatitis and primary hyperparathyroidism: is there a connection?

    by Anna M. Gorbacheva, Nataliya V. Zaytseva

    Hyperparathyroidism is a relatively frequent condition characterized by hypersecretion of parathyroid hormone. There are several forms of primary hyperparathyroidism. Each form affects its target region. In the visceral form, nephrocalcinosis, nephrolithiasis and peptic and duodenal ulcers are common. The pancreas is also a target organ. This article describes a clinical case of a patient with diabetes mellitus and previously treated primary hyperparathyroidism. The patient was admitted to the hospital due to poor glycaemic control. During the hospitalization, diabetes mellitus developed as a consequence of frequent relapses of chronic pancreatitis (outcome of the visceral form of primary hyperparathyroidism and severe hypertriglyceridemia). Glycaemic control was achieved after treatment of acute pancreatitis and insulin administration. This clinical case is an example of the impact of previous primary hyperparathyroidism (even after radical treatment and remission) on the development of a multi-faceted comorbidity.